Role: Hospital practitioner. PharmD, PhD, HDR

Theme: Biomarkers, Toxicology

Phone number:  05 55 05 80 35

Email address: souleiman.elbalkhi@chu-limoges.fr

Keywords: Diagnostic Biomarkers, Toxicology, Metals, Mass Spectrometry

Development of Diagnostic Biomarkers for Liver Damage:

1) Exchangeable Copper and Relative Exchangeable Copper (REC) for Wilson’s Disease Diagnosis: publications

2) Post-Translational Modifications of Albumin for the Diagnosis and Monitoring of Liver Damage (2 patents: US20220018852A1 and WO2024074685A1)

3) Post-Translational Modifications of Albumin for Early Rejection Identification in Transplanted Patients

4) Analytical Research and Development in LC-TOF for Protein Isoform Determination

June 2022 – Accreditation to Supervise Research: Post-Translational Modifications of Albumin as an Early Biomarker of Liver Damage. University of Limoges.

2007 – 2010 – PhD Thesis: Study of Copper Distribution in Plasma in Healthy Subjects and Patients with Wilson’s Disease. Identification of Biological Markers for the Diagnosis and Monitoring of Wilson’s Disease. Faculty of Pharmaceutical and Biological Sciences, Paris Descartes University – Paris V.

2005 – 2006 – University Diploma (DU): Specialized Training in Animal Experimentation. Faculty of Pharmacy, Paris Descartes University – Paris V.

2004 – 2005 – Master’s Degree (M2) in Research: Analytical Research and Development: “From the Active Molecule to its Bioanalysis”. Faculty of Pharmacy, Paris-Sud University 11.

Since 2014 – Hospital Practitioner – Clinical Biologist at the Department of Pharmacology, Toxicology, and Pharmacovigilance, Limoges University Hospital.

Since 2018 – Head of the Functional Unit “Environmental Analytical Toxicology”.

Since 2015 – Member of the INSERM UMR 1248 Unit “Pharmacology & Transplantation”.

Since 2015 – Judicial Expert in Toxicology and Analytical Toxicology at the Court of Appeal of Limoges.

Since 2021 – Chair of the Toxicology and Environmental Health Committee at the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT).

Over 55 articles published in journals indexed in the Science Citation Index

• 10 as first author
• 4 as second author
• 6 as second-to-last author
• 7 as last author

Average impact factor: 3.35
H-index: 18
Average number of citations per article: 9.6

Patent: EP No. 23306924.4